top of page

5-MEO Clinical trials to start on neuropsychiatric diseases


"Cosmo Feilding Mellen, co-founder and CEO, Beckley Psytech, says: “Our mission is to help patients in need by developing psychedelic medicines into licensed pharmaceuticals. This fundraise shows that our investors see the transformative potential of psychedelics as a new class of treatment for mental health and will enable us to accelerate our research and development programmes, as we prepare for our first clinical trial involving synthetic 5-MeO-DMT.”"

Read more.

22 views0 comments

Recent Posts

See All
bottom of page